Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-021-84137-5 http://scihub22266oqcxt.onion/10.1038/s41598-021-84137-5 33649382!7921444!33649382     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2021 ; 11 (1): 4814 Nephropedia Template TP {{tp|p=33649382|t=2021. Oncologic immunomodulatory agents in patients with cancer and COVID-19 |pdf=|usr=}}{{33649382}} gab.com Text Oncologic immunomodulatory agents in patients with cancer and COVID-19 JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33649382 #FOAvip Corticosteroids, anti-CD20 agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer. It is unclear how these agents affect patients with cancer who are infected with SARS-CoV-2. We retrospectively investigated associations between SARS-CoV-2-associated respiratory failure or death with receipt of the aforementioned medications and with pre-COVID-19 neutropenia. The study included all cancer patients diagnosed with SARS-CoV-2 at Memorial Sloan Kettering Cancer Center until June 2, 2020 (N = 820). We controlled for cancer-related characteristics known to predispose to worse COVID-19 as well as level of respiratory support during corticosteroid administration. Corticosteroid administration was associated with worse outcomes prior to use of supplemental oxygen; no statistically significant difference was observed in sicker cohorts. In patients with metastatic thoracic cancer, 9 of 25 (36%) and 10 of 31 (32%) had respiratory failure or death among those who did and did not receive immunotherapy, respectively. Seven of 23 (30%) and 52 of 187 (28%) patients with hematologic cancer had respiratory failure or death among those who did and did not receive anti-CD20 therapy, respectively. Chemotherapy itself was not associated with worse outcomes, but pre-COVID-19 neutropenia was associated with worse COVID-19 course. Relative prevalence of chemotherapy-associated neutropenia in previous studies may account for different conclusions regarding the risks of chemotherapy in patients with COVID-19. In the absence of prospective studies and evidence-based guidelines, our data may aid providers looking to assess the risks and benefits of these agents in caring for cancer patients in the COVID-19 era. Twit Text FOAVip Oncologic immunomodulatory agents in patients with cancer and COVID-19 ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33649382 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33649382 #FOAvip English Wikipedia <ref>{{Cite pmid|33649382}}</ref> Oncologic immunomodulatory agents in patients with cancer and COVID-19 #MMPMID33649382 Jee J; Stonestrom AJ; Devlin S; Nguyentran T; Wills B; Narendra V; Foote MB; Lumish M; Vardhana SA; Pastores SM; Korde N; Patel D; Horwitz S; Scordo M; Daniyan AF Sci Rep 2021[Mar]; 11 (1): 4814 PMID33649382show ga Corticosteroids, anti-CD20 agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer. It is unclear how these agents affect patients with cancer who are infected with SARS-CoV-2. We retrospectively investigated associations between SARS-CoV-2-associated respiratory failure or death with receipt of the aforementioned medications and with pre-COVID-19 neutropenia. The study included all cancer patients diagnosed with SARS-CoV-2 at Memorial Sloan Kettering Cancer Center until June 2, 2020 (N = 820). We controlled for cancer-related characteristics known to predispose to worse COVID-19 as well as level of respiratory support during corticosteroid administration. Corticosteroid administration was associated with worse outcomes prior to use of supplemental oxygen; no statistically significant difference was observed in sicker cohorts. In patients with metastatic thoracic cancer, 9 of 25 (36%) and 10 of 31 (32%) had respiratory failure or death among those who did and did not receive immunotherapy, respectively. Seven of 23 (30%) and 52 of 187 (28%) patients with hematologic cancer had respiratory failure or death among those who did and did not receive anti-CD20 therapy, respectively. Chemotherapy itself was not associated with worse outcomes, but pre-COVID-19 neutropenia was associated with worse COVID-19 course. Relative prevalence of chemotherapy-associated neutropenia in previous studies may account for different conclusions regarding the risks of chemotherapy in patients with COVID-19. In the absence of prospective studies and evidence-based guidelines, our data may aid providers looking to assess the risks and benefits of these agents in caring for cancer patients in the COVID-19 era. |*COVID-19 Drug Treatment[MESH] |*COVID-19/mortality[MESH] |*Hematologic Neoplasms/drug therapy/mortality[MESH] |*SARS-CoV-2[MESH] |Adrenal Cortex Hormones/*administration & dosage[MESH] |Aged[MESH] |Antineoplastic Agents, Immunological/*administration & dosage[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors/*administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH] |Neutropenia/drug therapy/mortality[MESH] |Respiratory Insufficiency[MESH]Oncologic immunomodulatory agents in patients with cancer and COVID-19(epmc).pdf DeepDyve Pubget Overpricing